Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries
This article, published in Pharmacoeconomics, provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries, followed by a comprehensive review of pharmacoeconomic analyses with the vaccine in low- and middle-income countries. The author found that, in numerous cost-effectiveness and sensitivity analyses, rotavirus vaccine RIX4414 generally remained cost effective even at the highest range of possible vaccine prices considered. Despite these results, decisions regarding the implementation of universal vaccination programs with RIX4414 may also be contingent on budgetary and other factors, underscoring the importance of subsidized vaccination programs for poor countries through the GAVI Alliance. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Plosker GL
Visit web page (English)
(Located at adisonline.com)
Citation: Plosker GL. Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries. Pharmacoeconomics. 2011;29(11):989-1009.